Geron Co. (NASDAQ:GERN) Receives $7.25 Average Price Target from Brokerages

Geron Co. (NASDAQ:GERN) has received an average rating of “Buy” from the eleven research firms that are covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation, eight have assigned a buy recommendation and two have issued a strong buy recommendation on the company. The average 1-year price target among brokerages that have covered the stock in the last year is $7.25.

A number of research firms have recently commented on GERN. Barclays raised Geron to a “strong-buy” rating in a research report on Friday, November 29th. Scotiabank initiated coverage on Geron in a research report on Wednesday, October 16th. They set a “sector outperform” rating and a $6.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and set a $9.00 price target on shares of Geron in a research report on Tuesday, December 10th. Finally, Needham & Company LLC lifted their target price on Geron from $6.00 to $7.00 and gave the stock a “buy” rating in a research note on Monday, January 13th.

Geron Price Performance

Geron stock opened at $3.02 on Tuesday. The business’s 50-day simple moving average is $3.60 and its 200 day simple moving average is $4.14. The stock has a market cap of $1.83 billion, a price-to-earnings ratio of -9.44 and a beta of 0.55. Geron has a 12-month low of $1.64 and a 12-month high of $5.34. The company has a quick ratio of 2.74, a current ratio of 2.89 and a debt-to-equity ratio of 0.04.

Geron (NASDAQ:GERN) last issued its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.05. Geron had a negative return on equity of 67.53% and a negative net margin of 682.48%. The firm had revenue of $28.27 million for the quarter, compared to analysts’ expectations of $18.97 million. During the same quarter last year, the business earned ($0.08) earnings per share. The company’s revenue was up 17138.4% compared to the same quarter last year. As a group, research analysts anticipate that Geron will post -0.25 earnings per share for the current year.

Institutional Trading of Geron

A number of institutional investors have recently modified their holdings of GERN. Darwin Global Management Ltd. acquired a new position in shares of Geron during the 2nd quarter worth $106,185,000. Renaissance Technologies LLC bought a new stake in shares of Geron in the 2nd quarter valued at about $3,315,000. RTW Investments LP bought a new stake in shares of Geron during the 3rd quarter valued at about $200,268,000. Algert Global LLC bought a new stake in shares of Geron during the 2nd quarter valued at about $539,000. Finally, Farallon Capital Management LLC boosted its position in shares of Geron by 124.6% during the 2nd quarter. Farallon Capital Management LLC now owns 16,837,000 shares of the biopharmaceutical company’s stock valued at $71,389,000 after purchasing an additional 9,342,000 shares in the last quarter. 73.71% of the stock is currently owned by institutional investors.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.